α4β7 integrin inhibitor programme for inflammatory bowel disease delivered compounds showing improved activity at a lower dose compared to example competitor clinical compounds in a pharmacodynamic model after oral dosing.C4XD signed an exclusive worldwide licensing agreement with AstraZeneca in November 2022, worth up to $402 million, for its NRF2 Activator programme.Sanofi is progressing C4XD’s IL-17A inhibitor programme for inflammatory diseases towards the next milestone.Indivior’s Phase 1 multiple ascending dose clinical trial of C4XD’s oral Orexin-1 receptor antagonist, C4X_3256 (INDV-2000), for substance use disorder is ongoing.Operational Highlights (including post-period events) With our proven expertise in drug discovery and our rigorous approach to programme development, we believe that a more focused approach on immuno-inflammatory diseases will allow us to harness our skillset and take the development of our programmes further, providing greater value for shareholders." "I’m excited that following a review of our expertise and previous successes, our strategy is now focused on treatments for immuno-inflammatory diseases. This external validation of our ability to generate high-quality small molecule discovery programmes builds on previous deals with globally recognised partners Sanofi and Indivior and brings our total potential deal value to $1.2 billion 1. "C4XD has continued to make significant strides across our portfolio during the period, culminating in our third global out-licensing deal, this time with AstraZeneca for our NRF2 Activator programme worth up to $402 million. MANCHESTER, United Kingdom, Ap(GLOBE NEWSWIRE) - C4X Discovery Holdings plc ( AIM: C4XD), a pioneering Drug Discovery company, today announces its half-year results for the six months ended 31 January 2023.ĭr Clive Dix, CEO of C4X Discovery, said: Launched PatientSeek, a Precision Medicine platform for optimised patient selection based on its Taxonom圓 ® genetic analysis technology Up to $402 million AstraZeneca deal for NRF2 Activator programme Third global out-licensing deal executedįuture strategic focus to deliver high value small molecules to treat immuno-inflammatory diseases Half-year results for the six months ended 31 January 2023 ("C4XD", "C4X Discovery" or the "Company") This announcement contains inside information
0 Comments
Leave a Reply. |